Core Insights - Arla Foods Ingredients has launched a new instant soluble whey protein ingredient, Lacprodan® BLG-100 Acidic, specifically designed for medical nutrition products to address common issues such as poor taste and adherence among patients [1][4] Industry Overview - Malnutrition is prevalent among hospitalized patients, with up to 50% affected, leading to extended hospital stays, decreased quality of life, increased mortality rates, and higher medical costs [3] - Many patients struggle to meet their protein intake through oral nutritional supplements due to poor taste and texture, with surveys indicating that about half of patients do not adhere to their clinical nutrition plans [3] Product Features - Lacprodan® BLG-100 Acidic provides 10 grams of high-quality whey protein per 100 milliliters, featuring excellent solubility and a pleasant taste without bitterness or astringency [4] - The product dissolves completely in both cold and hot beverages within 30 seconds, making it suitable for various applications, including full and non-full nutritional medical foods [4] - It contains all nine essential amino acids, particularly leucine, which is known to stimulate muscle protein synthesis, making it ideal for patients at risk of muscle loss [4][5] Application Potential - Arla Foods Ingredients has developed two innovative applications for Lacprodan® BLG-100 Acidic: a juice-based clinical nutrition drink and a milk-based ready-to-drink beverage, both of which can be easily mixed into various foods and drinks [5] - These products aim to provide patients with more flexible, convenient, and enjoyable options for increasing protein intake throughout the day [5]

Core Insights - Arla Foods Ingredients has launched a new casein glycomacropeptide ingredient, Lacprodan®CGMP-30, which has a lower phenylalanine content, aiming to improve dietary adherence and overall quality of life for patients with phenylketonuria (PKU) [1][4][6] Group 1: Product Development - The new Lacprodan®CGMP-30 reduces phenylalanine content by approximately 50% compared to its predecessor, Lacprodan®CGMP-20, making it particularly suitable for patients who are more sensitive to phenylalanine [4][5] - Lacprodan®CGMP-20 has already shown health benefits, including improved gastrointestinal comfort and taste, when partially replacing free amino acid-based protein substitutes [4][5][6] Group 2: Market Need - PKU is a genetic metabolic disorder affecting approximately 1 in 24,000 newborns globally, with a higher incidence in China at about 1 in 16,000 [3][4] - Dietary management for PKU patients is challenging due to the need for lifelong low-protein diets and the poor palatability of traditional protein substitutes [3][4] Group 3: Safety and Applications - Both Lacprodan®CGMP-30 and Lacprodan®CGMP-20 are considered safe protein sources for PKU management and can be used in medical nutrition applications, including UHT beverages and powders [5][6] - The ingredients are also suitable for other rare congenital amino acid metabolic disorders, such as tyrosinemia and alkaptonuria, due to their low tyrosine content [5][6]